Integrin
All Product Categories
-
Integrin Inhibitors
(180)
View all products
-
Integrin Agonists
(5)
View all products
-
Integrin Antagonists
(68)
View all products
-
Integrin Activators
(7)
View all products
-
Integrin Modulators
(5)
View all products
-
Integrin Chemicals
(2)
View all products
-
Integrin Inducers
(2)
View all products
-
Integrin Degrader
(1)
View all products
-
Integrin Controls
(3)
View all products
-
Integrin Substrate
(1)
View all products
-
Integrin Ligands
(15)
View all products
-
Integrin Verwandte Produkte (379)
Verwandte Produkte (379)
-
Lifitegrast-d4-1
0 ImagesArt. -Nr.: HY-19344S2Lifitegrast-d4-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.
-
Certepetide-13C6,15N2
0 ImagesArt. -Nr.: HY-P3448SSynonyms: CEND-1-13C6,15N2; iRGD-13C6,15N2; LSTA1-13C6,15N2Certepetide-13C6,15N2 (CEND-1-13C6,15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
-
Anti-Mouse CD41 Antibody (S-R690)
0 ImagesArt. -Nr.: HY-P991834
-
Fuzapladib potassium
0 ImagesArt. -Nr.: HY-19151BCAS. Nr.: 141284-74-4Synonyms: IS-741 potassiumFuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
-
RUC-1
0 ImagesArt. -Nr.: HY-124499CAS. Nr.: 796886-30-1RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice.
-
BMS-688521 (Standard)
0 ImagesArt. -Nr.: HY-10596RCAS. Nr.: 893397-44-9BMS-688521 (Standard) is the analytical standard of BMS-688521 (HY-10596). This product is intended for research and analytical applications. BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model.
-
Fradafiban
0 ImagesArt. -Nr.: HY-101720CAS. Nr.: 148396-36-5Synonyms: BIBU-52Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
-
SC-52012
0 ImagesArt. -Nr.: HY-19163CAS. Nr.: 145643-15-8HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.
-
Sibrafiban (Standard)
0 ImagesArt. -Nr.: HY-10309RCAS. Nr.: 172927-65-0Synonyms: RO 48-3657 (Standard)Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
-
EMD527040 (Standard)
0 ImagesArt. -Nr.: HY-101473RCAS. Nr.: 851333-14-7
-
BIO7662
0 ImagesArt. -Nr.: HY-123802CAS. Nr.: 327613-10-5
-
L123Z358
0 ImagesArt. -Nr.: HY-185470CAS. Nr.: 3110942-12-3L123Z358 is a ligand of αvβ6 integrin. L123Z358 can be conjugated with siRNA to achieve targeted drug delivery to muscle tissue.
-
Certepetide-13C2,15N
0 ImagesArt. -Nr.: HY-P3448S1Synonyms: CEND-1-13C2,15N; iRGD-13C2,15N; LSTA1-13C2,15NCertepetide-13C2,15N (CEND-1-13C2,15N) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
-
Orbofiban acetate (Standard)
0 ImagesArt. -Nr.: HY-10304ARCAS. Nr.: 163250-91-7Orbofiban acetate (Standard) is the analytical standard of Orbofiban acetate (HY-10304A). This product is intended for research and analytical applications. Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
-
Cyclo(RGDyK) trifluoroacetate (Standard)
0 ImagesCyclo(RGDyK) (trifluoroacetate) (Standard) is the analytical standard of Cyclo(RGDyK) (trifluoroacetate) (HY-100563). This product is intended for research and analytical applications. Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
-
Leukadherin-1 (Standard)
0 ImagesArt. -Nr.: HY-15701RCAS. Nr.: 344897-95-6Leukadherin-1 (Standard) is the analytical standard of Leukadherin-1. This product is intended for research and analytical applications. Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling.
-
Chrysotobibenzyl
0 ImagesArt. -Nr.: HY-122552CAS. Nr.: 108853-09-4Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394).
-
SR121566A
0 ImagesArt. -Nr.: HY-U00235CAS. Nr.: 180144-61-0SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
